Survodutide (BI 456906) Dosage Chart
Survodutide (BI 456906) is a once-weekly glucagon receptor and GLP-1 receptor dual agonist from Boehringer Ingelheim, studied for obesity, type 2 diabetes, and MASH. The glucagon arm is intended to add energy expenditure and direct hepatic fat mobilization on top of the appetite and glycemic effects of GLP-1.
Half-life
~4 days (~100 hours)
Format
Injectable
Purity
≥98%
Protocols
4 variants
Research Protocols
Dosage Protocols
Each row reflects a common research protocol variant. These are reference ranges derived from published literature and community research — not medical guidance.
Protocol 1
Obesity Dose-Finding (le Roux 2024, Phase 2)
Dose
Once-weekly SC, titrated to 0.6, 2.4, 3.6, or 4.8mg maintenance
Duration
20-week biweekly escalation, then 26 weeks maintenance (46 weeks total)
In 387 adults without diabetes, mean weight change at week 46 was -6.2% (0.6mg), -12.5% (2.4mg), -13.2% (3.6mg), and -14.9% (4.8mg) vs -2.8% for placebo. Gastrointestinal effects affected roughly 75% of survodutide recipients.
Protocol 2
MASH / Fibrosis (Sanyal 2024, Phase 2)
Dose
Once-weekly SC 2.4, 4.8, or 6.0mg
Duration
24-week escalation, then 24 weeks maintenance (48 weeks total)
MASH improvement without fibrosis worsening reached 47% (2.4mg), 62% (4.8mg), and 43% (6.0mg) vs 14% for placebo. This trial is the source of the 6.0mg top dose. Nausea, diarrhea, and vomiting were the dominant adverse events.
Protocol 3
Type 2 Diabetes (Blüher 2024, Phase 2)
Dose
Once-weekly SC up to 2.7mg (vs open-label semaglutide up to 1.0mg)
Duration
16 weeks
On a metformin background, HbA1c fell up to 1.71% and weight up to 8.7%. Survodutide at 1.8mg weekly and above beat semaglutide 1.0mg on weight loss. Slower escalation reduced the dose-related GI events.
Protocol 4
Slow-Escalation Research Pattern
Dose
Start 0.3mg once weekly, step up biweekly, hold at 2.4-4.8mg
Duration
20-24 week titration before assessing maintenance
Mirrors the trial escalation logic. Slow titration is the lever every survodutide trial used to keep nausea, vomiting, and diarrhea tolerable. Rushing the ladder drives dropouts.
Mixing Math
Reconstitution
Reference values for preparing a research vial. Adjust the syringe reading if you change the water volume.
Vial size
10mg vial
BAC water
1ml bacteriostatic water
Concentration
10mg/ml
Dose / ml
0.6mg = 0.06ml · 2.4mg = 0.24ml · 4.8mg = 0.48ml · 6.0mg = 0.6ml
Syringe units
6 IU (0.6mg) · 24 IU (2.4mg) · 48 IU (4.8mg) · 60 IU (6.0mg) on a U-100 syringe
Frequently Paired
Common Stacks
Storage
Handling Notes
Lyophilized: -20°C long-term, 2-8°C short-term. Reconstituted with bacteriostatic water: refrigerate at 2-8°C and use within about 28 days. Swirl gently, never shake or freeze the reconstituted solution.
Research Considerations
Cautions
- Gastrointestinal events are the dominant, dose-dependent signal: nausea up to 66%, diarrhea up to 49%, and vomiting up to 41% in the MASH trial. Slow biweekly titration is the mitigation used in every trial.
- GLP-1-class risks apply and are not yet ruled out at scale: pancreatitis, gallbladder events, and loss of lean mass alongside fat mass during rapid weight loss.
- The glucagon component can raise heart rate and, in theory, hepatic glucose output. Trials monitored both. Survodutide is still in Phase 3 (SYNCHRONIZE) and is not approved.
- Do not stack with semaglutide, tirzepatide, or retatrutide. Overlapping incretin mechanisms compound GI toxicity. Cagrilintide, an amylin analogue, acts on a distinct pathway.
Ready to start your research
Get Survodutide (BI 456906) from Ascension Peptides
COA-verified, US-based, discreet shipping. Use code ENHANCED for 50% off your entire order.
Buy Survodutide (BI 456906) nowResearch use only. Not medical advice. Browse all dosage charts